Skip to main content

Rosalind Advisors, Inc.

13F filer · CIK 0001622627
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$269MU.S. long equity reported on 13F
Positions293 new · 6 closed
Net flow last quarter-$17.7MBuys minus sells
Top 10 positions weight74.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202629 positions
DCTHDelcath Systems, Inc.$41.6M15.44%9.53%Not reportedQ4 2023
FENCFennec Pharmaceuticals Inc.$34.3M12.73%9.10%+9.6%Q4 2024
XERSXeris Biopharma Holdings, Inc.$23M8.56%1.68%-10.0%Q4 2023
SVRASavara Inc$19.6M7.27%1.55%-0.8%Q4 2024
VSTMVerastem, Inc.$15.2M5.66%4.41%+86.4%Q4 2024
XFORX4 Pharmaceuticals, Inc$15M5.58%3.34%Not reportedQ3 2025
EYPTEyePoint, Inc.$14.1M5.25%1.16%-4.7%Q3 2025
HELPCybin Inc.$12.9M4.80%3.79%+27.7%Q4 2024
VORVor Biopharma Inc.$11.9M4.44%1.19%-7.3%Q3 2024
PCVXVaxcyte, Inc.$11.6M4.32%0.14%-31.0%Q1 2026
MDWDMediWound Ltd.$11M4.09%5.84%Not reportedQ4 2023
CLDXCelldex Therapeutics, Inc.$7.44M2.76%0.25%-39.4%Q1 2026
BCRXBiocryst Pharmaceuticals Inc$7.22M2.68%0.28%-21.8%Q1 2026
PROFProfound Medical Corp.$5.51M2.05%2.27%Not reportedQ4 2023
TLPHTalphera, Inc.$5.32M1.98%9.96%+54.1%Q4 2023
AVIRAtea Pharmaceuticals, Inc.$4.98M1.85%1.33%-8.6%Q1 2026
MYOMyomo, Inc.$3.78M1.41%9.20%-5.4%Q4 2023
OVIDOvid Therapeutics Inc.$2.98M1.11%0.60%Not reportedQ2 2025
NRXSNeuraxis, INC$2.97M1.10%4.07%+77.6%Q4 2025
ABVXAbivax S.A.$2.78M1.03%0.03%Not reportedQ1 2024
NSPRInspireMD, Inc.$2.73M1.02%8.32%Not reportedQ4 2023
RGNTRegentis Biomaterials Ltd.$2.48M0.92%13.55%+179.0%Q4 2025
PYPDPolyPid Ltd.$1.98M0.73%2.14%-34.9%Q1 2024
BFRIBiofrontera Inc.$1.21M0.45%8.98%+9.6%Q1 2024
KURAKura Oncology, Inc.$1.1M0.41%0.11%Not reportedQ1 2025
SPRBSpruce Biosciences, Inc.$1.08M0.40%0.73%Not reportedQ4 2023
AQSTAquestive Therapeutics, Inc.$1.04M0.39%0.20%Not reportedQ1 2026
OKUROnKure Therapeutics, Inc.$684K0.25%0.37%-66.2%Q4 2025
PEPGPepGen Inc.$630K0.23%0.51%NewQ2 2026
Q1 2026Reported May 14, 202632 positions
DCTHDelcath Systems, Inc.$30.6M12.31%9.58%Not reportedQ4 2023
XERSXeris Biopharma Holdings, Inc.$18.7M7.53%1.87%+53.0%Q4 2023
FENCFennec Pharmaceuticals Inc.$17.9M7.19%8.42%+11.3%Q4 2024
SVRASavara Inc$17.5M7.03%1.56%-5.9%Q4 2024
PCVXVaxcyte, Inc.$16.9M6.77%0.20%NewQ1 2026
EYPTEyePoint, Inc.$13.4M5.37%1.24%+50.3%Q3 2025
XFORX4 Pharmaceuticals, Inc$13.3M5.33%3.41%+23.4%Q3 2025
VORVor Biopharma Inc.$12.5M5.02%1.29%Not reportedQ3 2024
MDWDMediWound Ltd.$12.1M4.85%5.84%Not reportedQ4 2023
VSTMVerastem, Inc.$11.3M4.55%2.43%+19.6%Q4 2024
CLDXCelldex Therapeutics, Inc.$10.5M4.21%0.50%NewQ1 2026
BCRXBiocryst Pharmaceuticals Inc$8.79M3.53%0.36%NewQ1 2026
HELPCybin Inc.$7.35M2.95%2.97%-7.6%Q4 2024
CGONCG Oncology, Inc.$6.77M2.72%0.11%-66.7%Q2 2025
NSPRInspireMD, Inc.$6.37M2.56%8.34%Not reportedQ4 2023
AVIRAtea Pharmaceuticals, Inc.$6.3M2.53%1.46%NewQ1 2026
PROFProfound Medical Corp.$5.37M2.16%2.28%-22.5%Q4 2023
VRDNViridian Therapeutics, Inc.\DE$4.9M1.97%0.24%-44.4%Q4 2023
PYPDPolyPid Ltd.$2.62M1.05%3.28%-14.2%Q1 2024
MYOMyomo, Inc.$2.6M1.04%9.98%+0.2%Q4 2023
TLPHTalphera, Inc.$2.51M1.01%6.70%-6.3%Q4 2023
OVIDOvid Therapeutics Inc.$2.46M0.99%0.66%Not reportedQ2 2025
DFTXDefinium Therapeutics, Inc.$2.36M0.95%0.12%NewQ1 2026
OKUROnKure Therapeutics, Inc.$1.84M0.74%3.25%-39.3%Q4 2025
LPCNLipocine Inc.$1.77M0.71%2.96%NewQ1 2026
NRXSNeuraxis, INC$1.69M0.68%2.50%Not reportedQ4 2025
AVTXAvalo Therapeutics, Inc.$1.12M0.45%0.30%NewQ1 2026
ANNXAnnexon, Inc.$1.11M0.45%0.13%NewQ1 2026
AQSTAquestive Therapeutics, Inc.$1.04M0.42%0.20%NewQ1 2026
BFRIBiofrontera Inc.$942K0.38%9.80%+2.0%Q1 2024
KURAKura Oncology, Inc.$813K0.33%0.11%Not reportedQ1 2025
RGNTRegentis Biomaterials Ltd.$768K0.31%4.86%Not reportedQ4 2025
Q4 2025Reported Feb 12, 202629 positions
DCTHDelcath Systems, Inc.$33M11.60%9.51%Not reportedQ4 2023
SVRASavara Inc$20.5M7.21%1.66%-14.9%Q4 2024
FENCFennec Pharmaceuticals Inc.$20.1M7.07%7.65%+25.8%Q4 2024
XERSXeris Biopharma Holdings, Inc.$16.6M5.83%1.27%+17.6%Q4 2023
VRDNViridian Therapeutics, Inc.\DE$14M4.92%0.44%-25.0%Q4 2023
MDWDMediWound Ltd.$13.8M4.86%5.84%Not reportedQ4 2023
VSTMVerastem, Inc.$13.8M4.85%2.30%-7.3%Q4 2024
REPLReplimune Group, Inc.$13.7M4.82%1.77%Not reportedQ4 2024
ATYRaTYR PHARMA INC$13.6M4.78%1.06%Not reportedQ3 2025
HELPCybin Inc.$13.6M4.77%7.67%+10.5%Q4 2024
EYPTEyePoint, Inc.$12.6M4.43%0.83%+6.2%Q3 2025
CGONCG Oncology, Inc.$12.5M4.38%0.37%Not reportedQ2 2025
CYTKCytokinetics Inc$12.4M4.36%0.16%-51.2%Q2 2025
XFORX4 Pharmaceuticals, Inc$10.4M3.66%2.87%+68.7%Q3 2025
MNMDDefinium Therapeutics, Inc.$10M3.53%Not reportedNot reportedQ1 2025
PROFProfound Medical Corp.$8.41M2.96%2.95%+54.4%Q4 2023
NSPRInspireMD, Inc.$6.95M2.44%8.97%Not reportedQ4 2023
OCULOcular Therapeutix, Inc$4.86M1.71%0.19%Not reportedQ2 2024
AVBPArriVent BioPharma, Inc.$4.34M1.53%0.51%NewQ4 2025
TLPHTalphera, Inc.$4.08M1.43%7.26%-18.4%Q4 2023
MYOMyomo, Inc.$3.49M1.23%9.98%+1.3%Q4 2023
PYPDPolyPid Ltd.$3.02M1.06%3.83%-24.2%Q1 2024
OKUROnKure Therapeutics, Inc.$2.12M0.74%218.48%NewQ4 2025
RGNTRegentis Biomaterials Ltd.$1.7M0.60%4.86%NewQ4 2025
TRVITrevi Therapeutics, Inc.$1.25M0.44%0.08%Not reportedQ4 2023
NRXSNeuraxis, INC$1.04M0.37%2.69%NewQ4 2025
KURAKura Oncology, Inc.$1.04M0.37%0.11%Not reportedQ1 2025
GUTSFractyl Health, Inc.$849K0.30%0.25%-92.3%Q3 2025
BFRIBiofrontera Inc.$650K0.23%9.79%Not reportedQ1 2024
Q3 2025Reported Nov 13, 202529 positions
DCTHDelcath Systems, Inc.$33M11.28%9.35%Not reportedQ4 2023
CYTKCytokinetics Inc$22M7.51%0.33%Not reportedQ2 2025
FENCFennec Pharmaceuticals Inc.$19.4M6.64%7.40%+1.5%Q4 2024
VSTMVerastem, Inc.$17M5.82%2.89%-5.6%Q4 2024
RZLTRezolute, Inc.$17M5.81%1.99%+3.8%Q1 2024
XERSXeris Biopharma Holdings, Inc.$14.6M5.00%1.08%-16.7%Q4 2023
SVRASavara Inc$14.3M4.88%2.31%+50.7%Q4 2024
MDWDMediWound Ltd.$13.5M4.61%6.94%+84.0%Q4 2023
VRDNViridian Therapeutics, Inc.\DE$12.9M4.43%0.73%-14.3%Q4 2023
CGONCG Oncology, Inc.$12.1M4.13%0.38%+55.5%Q2 2025
VRNAVerona Pharma plc$10.7M3.65%0.01%Not reportedQ4 2023
IDYAIDEAYA Biosciences, Inc.$9.52M3.26%0.40%-31.5%Q1 2025
NSPRInspireMD, Inc.$9.41M3.22%9.32%+70.6%Q4 2023
EYPTEyePoint, Inc.$9.26M3.16%0.93%NewQ3 2025
MNMDDefinium Therapeutics, Inc.$8.84M3.02%Not reported+78.6%Q1 2025
HELPCybin Inc.$8.84M3.02%6.94%+85.0%Q4 2024
GUTSFractyl Health, Inc.$7.95M2.72%3.78%NewQ3 2025
ATYRaTYR PHARMA INC$7.56M2.59%1.06%NewQ3 2025
QUREuniQure N.V.$7.3M2.49%0.20%NewQ3 2025
XFORX4 Pharmaceuticals, Inc$5.28M1.81%6.14%NewQ3 2025
OCULOcular Therapeutix, Inc$4.68M1.60%0.23%-67.2%Q2 2024
TLPHTalphera, Inc.$3.92M1.34%9.62%+118.9%Q4 2023
PROFProfound Medical Corp.$3.38M1.16%2.29%Not reportedQ4 2023
MYOMyomo, Inc.$3.38M1.16%9.86%+5.4%Q4 2023
PYPDPolyPid Ltd.$3.06M1.05%5.87%-5.8%Q1 2024
BFRIBiofrontera Inc.$1.12M0.38%9.79%+16.8%Q1 2024
ATXSAstria Therapeutics, Inc.$1.11M0.38%2.73%Not reportedQ4 2023
TRVITrevi Therapeutics, Inc.$915K0.31%0.08%-66.7%Q4 2023
KURAKura Oncology, Inc.$885K0.30%0.11%Not reportedQ1 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.